Editas Medicine, INC 10-Q quarterly reports

Editas Medicine's Q2 2026 Form 10-Q reveals increased collaboration revenue, reduced operating expenses due to workforce reduction, and progress on its lead EDIT-401 program, alongside a successful equity offering.

Editas Medicine reports reduced net loss and extended cash runway into Q3 2027 following a strategic shift to in vivo gene editing and significant restructuring.

Editas Medicine reports reduced net losses and extended cash runway into Q2 2027 following a strategic pivot to in vivo gene editing and significant restructuring.

Editas Medicine reports a net loss of $76.1 million for Q1 2025, shifting focus to in vivo gene editing and advancing preclinical programs.

Editas Medicine reported a net loss of $62.1 million for the third quarter of 2024, while highlighting progress in its clinical programs and strategic shifts towards in vivo gene editing.

Editas Medicine's Q2 2024 report highlights increased R&D spending, progress in clinical trials for reni-cel, and a net loss of $67.6 million.

Editas Medicine reported a net loss of $61.95 million for the first quarter of 2024, with increased research and development expenses and a decrease in collaboration revenue.